{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:00:03Z","timestamp":1788559203472,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010571","name":"BMBF Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jacbts.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T18:39:15Z","timestamp":1717612755000},"page":"890-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression"],"prefix":"10.1016","volume":"9","author":[{"given":"Ekaterina","family":"Legchenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chouvarine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimunnisa","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Specker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Nazar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Matthes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-3935","authenticated-orcid":false,"given":"Georg","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2024.04.006_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2024.04.006_bib2","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2017.03.575","article-title":"Pulmonary hypertension in infants, children, and young adults","volume":"69","author":"Hansmann","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacbts.2024.04.006_bib4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jpeds.2012.05.062","article-title":"Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus","volume":"161","author":"Wickremasinghe","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jacbts.2024.04.006_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0050-2019","article-title":"Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations","volume":"28","author":"Swinnen","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jacbts.2024.04.006_bib6","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.jacc.2020.03.047","article-title":"Challenges and special aspects of pulmonary hypertension in middle- to low-income regions: JACC state-of-the-art review","volume":"75","author":"Hasan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib7","first-page":"2268","article-title":"Riociguat for pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib8","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herve","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn","volume":"354","author":"Chambers","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib13","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1002\/cphy.c220004","article-title":"Serotonin and pulmonary hypertension; sex and drugs and ROCK and rho","volume":"12","author":"MacLean","year":"2022","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0006-2952(03)00556-2","article-title":"A\u00a0unique central tryptophan hydroxylase isoform","volume":"66","author":"Walther","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.1078197","article-title":"Synthesis of serotonin by a second tryptophan hydroxylase isoform","volume":"299","author":"Walther","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2024.04.006_bib16","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/CIRCULATIONAHA.105.591321","article-title":"Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia","volume":"113","author":"Eddahibi","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.006_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/mt.2012.70","article-title":"Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension","volume":"20","author":"Morecroft","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jacbts.2024.04.006_bib18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201103-0412OC","article-title":"A\u00a0novel murine model of severe pulmonary arterial hypertension","volume":"184","author":"Ciuclan","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib19","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1161\/CIRCULATIONAHA.108.767558","article-title":"Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice","volume":"117","author":"Dempsie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.006_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000252210.58849.78","article-title":"Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension","volume":"49","author":"Morecroft","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2024.04.006_bib21","doi-asserted-by":"crossref","first-page":"L1045","DOI":"10.1152\/ajplung.00082.2007","article-title":"Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice","volume":"293","author":"Izikki","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib22","doi-asserted-by":"crossref","first-page":"L500","DOI":"10.1152\/ajplung.00049.2012","article-title":"Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice","volume":"303","author":"Abid","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.116.237933","article-title":"Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension","volume":"360","author":"Aiello","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacbts.2024.04.006_bib24","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.chest.2021.10.010","article-title":"Novel mechanisms targeted by drug trials in pulmonary arterial hypertension","volume":"161","author":"Condon","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jacbts.2024.04.006_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12088","article-title":"A\u00a0trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)","volume":"12","author":"Lazarus","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jacbts.2024.04.006_bib26","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1021\/acs.jmedchem.2c00598","article-title":"Structure-based design of xanthine-benzimidazole derivatives as novel and potent tryptophan hydroxylase inhibitors","volume":"65","author":"Specker","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jacbts.2024.04.006_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0303","article-title":"The PPAR\u03b3 agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation","volume":"10","author":"Legchenko","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107423","article-title":"Inhibition of serotonin synthesis: a novel therapeutic paradigm","volume":"205","author":"Bader","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacbts.2024.04.006_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fphar.2017.00240","article-title":"Identification of a novel allosteric inhibitory site on tryptophan hydroxylase 1 enabling unprecedented selectivity over all related hydroxylases","volume":"8","author":"Petrassi","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacbts.2023.06.014","article-title":"Development of a peripherally restricted 5-HT2B partial agonist for treatment of pulmonary arterial hypertension","volume":"8","author":"Valentine","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2024.04.006_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148657","article-title":"Serotonin 2B receptor antagonism prevents heritable pulmonary arterial hypertension","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2024.04.006_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.RES.0000215809.47923.fd","article-title":"Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice","volume":"98","author":"Long","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2024.04.006_bib34","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","article-title":"An antiproliferative BMP-2\/PPAR\u03b3\/apoE axis in human and murine SMCs and its role in pulmonary hypertension","volume":"118","author":"Hansmann","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacbts.2024.04.006_bib35","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/CIRCULATIONAHA.106.663120","article-title":"Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator\u2013activated receptor-gamma activation","volume":"115","author":"Hansmann","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.04.006_bib36","doi-asserted-by":"crossref","first-page":"72910","DOI":"10.18632\/oncotarget.20582","article-title":"5-HT induces PPAR \u03b3 reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3\u03b2\/\u03b2-catenin pathway","volume":"8","author":"Ke","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jacbts.2024.04.006_bib37","doi-asserted-by":"crossref","first-page":"17525","DOI":"10.1074\/jbc.M210465200","article-title":"Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells","volume":"278","author":"Suzuki","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2024.04.006_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.phrs.2009.01.007","article-title":"Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells","volume":"59","author":"Li","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacbts.2024.04.006_bib39","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbrc.2018.01.150","article-title":"FABP4 inhibitors suppress inflammation and oxidative stress in murine and cell models of acute lung injury","volume":"496","author":"Gong","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacbts.2024.04.006_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.apha.2016.07.001","article-title":"Potassium channels in regulation of vascular smooth muscle contraction and growth","volume":"78","author":"Jackson","year":"2017","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00062752-200009000-00001","article-title":"Plasma kallikrein\/kinin system: a revised hypothesis for its activation and its physiologic contributions","volume":"7","author":"Schmaier","year":"2000","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107858","article-title":"Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities","volume":"226","author":"Samidurai","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacbts.2024.04.006_bib43","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib44","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41419-019-1765-0","article-title":"Long noncoding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jacbts.2024.04.006_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/heartjnl-2015-308365","article-title":"Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension","volume":"102","author":"Calvier","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jacbts.2024.04.006_bib46","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1089\/ars.2019.7753","article-title":"Galectin-3: a harbinger of reactive oxygen species, fibrosis, and inflammation in pulmonary arterial hypertension","volume":"31","author":"Fulton","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jacbts.2024.04.006_bib47","doi-asserted-by":"crossref","first-page":"L784","DOI":"10.1152\/ajplung.00186.2018","article-title":"Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis","volume":"316","author":"Barman","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib48","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201711-2308LE","article-title":"Galectin-3 promotes vascular remodeling and contributes to pulmonary hypertension","volume":"197","author":"Barman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacbts.2024.04.006_bib49","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.18632\/aging.102922","article-title":"RNA sequencing analysis of monocrotaline-induced PAH reveals dysregulated chemokine and neuroactive ligand receptor pathways","volume":"12","author":"Xiao","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jacbts.2024.04.006_bib50","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor\u2013associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-\u03baB, Elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib51","doi-asserted-by":"crossref","first-page":"H190","DOI":"10.1152\/ajpheart.00644.2020","article-title":"Inhibition of iNOS augments cutaneous endothelial NO-dependent vasodilation in prehypertensive non-Hispanic Whites and in non-Hispanic Blacks","volume":"320","author":"Miller","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacbts.2024.04.006_bib52","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.3390\/ijms19123805","article-title":"Regulation of iNOS on immune cells and its role in diseases","volume":"19","author":"Xue","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X2400175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X2400175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:50:21Z","timestamp":1736502621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X2400175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2452302X2400175X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2024.04.006","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}